Interaction of reverse transcriptase (RT) mutations conferring resistance to lamivudine and etravirine: effects on fitness and RT activity of human immunodeficiency virus type 1.
Abstract: Clinical trials of RPV administered with lamivudine or emtricitabine showed the emergence of E138K together with M184I, which confers lamivudine and emtricitabine resistance in most patients with virologic failure.
Abstract: Fitness profiles and growth competition experiments showed that the E138K/M184I mutant had a significant replicative advantage over the E138K/M184V mutant in the presence of etravirine and lamivudine.
Abstract: The RC of the E138K/M184I mutant in the presence of etravirine was significantly greater than that of the E138K and E138K/M184V mutants; the RC of the double m
Compensation by the E138K mutation in HIV-1 reverse transcriptase for deficits in viral replication capacity and enzyme processivity associated with the M184I/V mutations.
Abstract: E138K restored viral replication capacity (RC) in the presence of M184I/V, and this was confirmed in cell-free RT processivity assays.
Abstract: In contrast, M184I/V resulted in an increased K(m) for dNTPs compared to those for WT RT.
Abstract: Recently, several phase 3 clinical trials (ECHO and THRIVE) showed that E138K and M184I were the most frequent mutations to emerge in patients who failed therapy with rilpivirine (RPV) together with two nucleos(t)ide reverse transcriptase inhibitors, emtricitabine (FTC) and tenofovir (TDF).
Abstract: Structural modeling shows that the addition of E138K to M184I/
Next-generation sequencing of dried blood spot specimens: a novel approach to HIV drug-resistance surveillance.
Abstract: An exception was an M184I mutation only detected with TPP of DBS at a frequency of 20.4%.
Drug resistance patterns and virus re-suppression among HIV-1 subtype C infected patients receiving non-nucleoside reverse transcriptase inhibitors in South Africa.
PMID: 21927716
2011
Journal of AIDS & clinical research
Result: Finally 14/38 (37%) had >=4 mutations: 13/14 (93%) M184V/I and 8/14 (57%) K103N, all with >=2 NNRTI and most with one or more thymidine analogue mutations (TAM) or other NRTI mutations.
Result: Of the genotyped samples 5/38 (13%) had K103N alone; 2/38 (5%) had M184V and K103N; and 10/38 (26%) had three mutations with M184V/I, K103N and an additional NNRTI mutation.
Discussion: 83% among published sequences), >=1 NRTI resistance mutations (11% vs 9%), the prevalence of K103N (55% vs 42%), M184V/I
Increase of transmitted drug resistance among HIV-infected sub-Saharan Africans residing in Spain in contrast to the native population.
Discussion: Finally, the surprisingly high rate in native Spanish of RT-M184I/V (4.4%), a mutation rapidly cleared due to its cost in terms of viral fitness, might reflect an unrecorded previous treatment exposure in some patients.
Discussion: On the other hand, the correlation between HIV subtype and birth place of the patients could also have confused the different mutational pattern described: the preferential presence of NRTI-resistance mutation M184I/V in SSA compared to T215revertants in Spanish and CSA could appear to be associated to the infection by non-B variants and subtype B, respectively, as reported in other countries.
Discussion: Our observation of a lower viral load among patients infected with variants carrying M184I/V has previously been described due to the fitness reduct
Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: a bayesian analysis.
Result: The most prevalent NRTI mutations in both NNRTI groups were M184V/I (93% in nevirapine and 66% in efavirenz).
Discussion: Our analysis, shown in Figure 2D, confirmed that the M184I mutation occurs before M184V, suggested that K103N is an early mutation, and showed clearly that all the TAM-2 pathway mutations, as well as 215Y, occur as time spent on virologic failure increases.
Does GSS still maintain relevance on HAART outcome after the introduction of newest active antiretroviral drugs? 48 weeks results.
Abstract: Data also showed a > 60% recurrence of specific mutations for NRTI: M41L, M184IV, L210W, T215FY, K219EQ and 75% for D67N.
[Studying on the prevalence and mutation pattern of N348I which related to the resistance of HIV-1].
PMID: 22340881
2011
Zhonghua liu xing bing xue za zhi
Abstract: N348I always emerged, and combined with others mutations among patients of ART, whose frequencies were: 85.0% in combination with thymidine analog mutations (TAMs) and 52.5% with M184V/I, respectively.
Varied patterns of HIV-1 drug resistance on failing first-line antiretroviral therapy in South Africa.
PMID: 19801944
2010
Journal of acquired immune deficiency syndromes (1999)
Abstract: RESULTS: The most common reverse transcriptase mutation was M184V/I (72%; n = 163); 11% of patients (n = 25) had only nonnucleoside reverse transcriptase inhibitor (NNRTI) mutations and 17% (n = 38) had no known resistance mutations.
Postpartum antiretroviral drug resistance in HIV-1-infected women receiving pregnancy-limited antiretroviral therapy.
Abstract: In women receiving dual or triple PLAT, respectively, postpartum M184V/I rates were 65% (95% by ASPCR) and 28.7% (51.6% by ASPCR), respectively (P < 0.01).
Result: Using population sequencing of plasma viruses, the M184V/I mutation was detected postpartum in 65.0% of women receiving dual PLAT throughout pregnancy compared to 28.7% of women treated with 3 drugs (p=0.004).
HIV mutation literature information.
PMID: 
2011
Journal of virology
Browser Board
Co-occurred Entities
Filtrator
ViMRT